View All Key Stats
LLY Key Stats
| Income Statement | |
| Revenue (TTM) | 22.00B |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 2.31 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 2.447B |
| Profitability | |
| Gross Profit Margin (Quarterly) | 73.36% |
| Profit Margin (Quarterly) | 17.31% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | 2.68% |
| Price and Valuation | |
| Market Cap | 85.19B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 3.767 |
| PE Ratio (TTM) | 33.50 |
| Price to Book Value | 6.072 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | 0.7303 |
| Free Cash Flow (Quarterly) | -660.90M |
| Return on Equity (TTM) | 14.92% |
View All LLY News
LLY News
-
WireHeadlineTime (ET)
-
PR Newswire08/21 10:44
-
Yahoo08/18 16:47
-
Yahoo08/18 10:38
-
PR Newswire08/17 23:01
-
Yahoo08/17 12:17
-
Yahoo08/17 11:12
-
PR Newswire08/17 06:15
-
Yahoo08/17 00:44
-
Yahoo08/16 18:36
-
SA Breaking News08/16 15:05
View All Events
LLY Events
| Date | Type | Description |
|---|---|---|
| 08/11/2017 | Dividends | Amount: 0.52, Declared Date: Jun 19 2017, Pay Date: Sep 08 2017 |
| 07/25/2017 09:00 EDT | Misc | Eli Lilly and Co Second Quarter Earnings Conference Call in 2017 |
| 07/25/2017 | Earnings | Eli Lilly and Co Second Quarter Earnings in 2017 Release |
| 05/11/2017 | Dividends | Amount: 0.52, Declared Date: May 02 2017, Pay Date: Jun 09 2017 |
| 05/01/2017 | Misc | Eli Lilly and Co Annual General Meeting in 2016 |
| 04/25/2017 09:00 EST | Misc | Eli Lilly and Co First Quarter Earnings Conference Call in 2017 |
| 04/25/2017 | Earnings | Eli Lilly and Co First Quarter Earnings in 2017 Release |
| 03/01/2017 | Misc | Lilly Completes Acquisition of Colucid Pharmaceuticals |
| 02/13/2017 | Dividends | Amount: 0.52, Declared Date: Dec 12 2016, Pay Date: Mar 10 2017 |
| 01/31/2017 09:00 EDT | Misc | Eli Lilly and Co Fourth Quarter Earnings Conference Call in 2016 |
LLY Fundamentals
Income Statement View Statement
LLY Ratings
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
Advertisement
LLY One Page Reports
- One Page Report Download
LLY Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Target Price | |
| Price | 77.38 |
| Price Target | Upgrade |
Edit
Profile
- URL: http://www.lilly.com
- Investor Relations URL: https://investor.lilly.com/
- HQ State/Province: Indiana
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
- Next Earnings Release: N/A
- Last Earnings Release: Jul. 25, 2017
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: Aug. 11, 2017
- Description: Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.
LLY Comparables
EditLLY Excel Add-In Codes
- Name: =YCI("LLY","name")
- Description: =YCI("LLY","description")
- Sector: =YCI("LLY","sector")
- Industry: =YCI("LLY","industry")
- Est. Current Fiscal Year End: =YCI("LLY","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other LLY Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- LLY Tweets Stocktwits
Advertisement
